Motilal Oswal
Management said that SUNP aims to sustain its outperformance in the domestic formulation (DF) segment through increased doctor engagement, new launches, addition of field force and strengthening the brand recall of its existing products.
Sun Pharmaceutical I.. has an average target of 2050.25 from 8 brokers.
More from Sun Pharmaceutical Industries Ltd.
Recommended